The Survey of relationship between Serum Resistin Level and Metabolic Syndrome Components in patients with and without this syndrome in Rafsanjan (2015)

Background &Objective: Resistin is an adipokin secreted from adipose tissue and immunity cells. Relationship between resistin and metabolic syndrome and its components is controversial. The aim of this study is measurement of serum resistin level, insulin resistance and other factors in subjects with and without metabolic syndrome. Materials & Methods: this cross-sectional study was conducted in 2015, 56 availableperson including; 31subjects were enrolled as the study group and 25 subjects were recruited as the control group of the study. Serum resistin concentrations were measured by ELISA and its association with metabolic syndrome markers was measured. Data were Analyzed using independent T test, Pearson correlation Test and, Chi-squared Test Results: Serum resistin levels were significantly higher in the metabolic syndrome subject compared with control group (p-value=0.002). Correlation analysis revealed body mass index (p=0.018; r=0.480), waist circumference (p=0.015; r=0.431), systolic blood pressure (p=0.008; r=0.467), diastolic blood pressure (p=0.001; r=0.562), cholesterol (p=0.018; r=0.421) and LDL (p=0.003; r=0.515) were positively correlated with plasma resistin. Conclusion: Serum resistin levels are elevated in subjects with metabolic syndrome and are associated with some of its components in metabolic syndrome patients, resistin may be associated with the severity of this syndrome and its complications

Health impact and related cost of ambient air pollution in Tehran

Ambient air pollution represents one of the biggest environmental risks to health. In this study, we estimated the avoidable mortality burden attributable to ambient air pollution in Tehran, and derived the economic impact associated with these health effects. Using PM; 2.5; data from ground-level air pollution measurements in Tehran, we estimated PM; 2.5; exposure for 349 neighborhoods in Tehran, by the Environmental Benefits Mapping and Analysis Program (BenMAP-CE). We considered five scenarios related to PM; 2.5; levels: an increase to 35 μg/m; 3; ; a reduction to 25 μg/m; 3; ; a reduction to 15 μg/m; 3; ; a reduction to 10 μg/m; 3; (the WHO's air quality guideline value); and a full roll-back, assuming a reduction to 2.4 μg/m; 3; . All scenarios used 2017 p.m.; 2.5; levels as a starting point. Using the concentration response function of the Global Exposure Mortality Model (GEMM), we estimated a total of 7146 (95% CI: 6596-7513) adult (age ≥25 years) deaths attributable to PM; 2.5; in 2017. The leading causes of death were ischemic heart disease (3437; 95% CI: 3315-3516), stroke (886; 95% CI: 693-1002), lower respiratory infections (531: 95% CI: 414-589), chronic obstructive pulmonary disease (364; 95% CI: 271-420), and lung cancer (274; 95% CI: 236-298). The estimated total annual economic benefit (2017) of reducing PM; 2.5; concentration levels to 2.4 μg/m; 3; was USD 0.591 (95% CI: 0.447-0.624) billion per year, using the value of a life year (VOLY) approach, and USD 2.894 (95% CI: 2.671-3.043) billion per year, using the value of a statistical life (VSL) approach